Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.53, ...

Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

In a report released yesterday, Chris Shibutani from Goldman Sachs upgraded BioNTech SE (BNTX – Research Report) to a Buy, with a price ...

BioNTech stock jumped on Monday after the German company reported unexpected profit and walloped sales expectations for the third quarter.

On Monday, BioNTech SE (NASDAQ:BNTX) reported third-quarter revenues of 1.244 billion euros (or $1.36 billion), up from 895.3 ...

BioNTech (NASDAQ:BNTX – Get Free Report) will be announcing its earnings results before the market opens on Monday, November 4th. Analysts expect the company to announce earnings of ($1.06) per share ...

BioNTech's stock has risen by 24% since March, outperforming the S&P 500, driven by optimism in their oncology pipeline. Despite a partial FDA hold on BNT316/ONC-392 for NSCLC, other trials and ...

We expect BioNTech SE BNTX to surpass expectations when it reports third-quarter 2024 results on Nov. 4, before the opening bell. Let’s see how things have shaped up for the quarter to be reported.

BioNTech's stock performance will likely be influenced by the outcomes of the upcoming Phase 3 trials and the company's ability to meet the lower end of its 2024 revenue guidance. Investors and market ...

BioNTech reported better-than-expected quarterly results helped by solid sales of its variant-adapted Covid-19 vaccines.